Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
These cognitive deficits may suggest that cognitive therapy
2019-11-02

These cognitive deficits may suggest that cognitive therapy and pharmacotherapy for gambling behavior may ultimately wish to consider genotyping as a means of better targeting treatment approaches. If core cognitive deficits are shown consistently in certain subgroups of gamblers based on genotype,
-
br Materials and methods br Results br Discussion The EP
2019-11-02

Materials and methods Results Discussion The EP4 NVP-BSK805 for PGE2 is similar to the EP1, EP2 and EP3 receptors in that they all have seven transmembrane segments and are coupled to Gα subunits of heterotrimeric G proteins, with a different Gα subunit for each receptor (Sugimoto and Naru
-
Since the dideoxy analogues and served as substrates for
2019-11-02

Since the 1,2-dideoxy analogues, and , served as substrates for TgTCEA and TgTCEB, respectively, with the higher affinity (lower ) and lower turnover number (lower ) than their authentic substrates, PosA and PosB (such trend was more evident on analogue for TgTCEB than on analog for TgTCEA), an intr
-
Currently approved anti obesity drugs for long term
2019-11-01

Currently approved anti-obesity drugs for long term use such as orlistat, lorcaserin and liraglutide are efficient in reduction of weight gain but are limited in usage due to their adverse effect profile and higher cost (Krentz et al., 2016; Mopuri and Islam, 2017). In AZ20 to this, plant derived m
-
The differences between ground and
2019-11-01

The differences between ground and transition state properties are exemplified by a comparison of our human–yeast results with those of a structural study of possible differences in ubiquitin-Uba-1 binding in yeast (known structure) with human (simulated in [12]). Their discussion focuses on Ubiquit
-
The most significant source of DAG originates from
2019-11-01

The most significant source of DAG originates from the PLC family of enzymes, which produces DAG in an agonist-regulated reaction. PLCs constitute a wide family of enzymes acting on both phosphatidilinositols (PI) and phosphatidilcoline (PC) (Li et al., 2010) in the plasma membrane and other intrace
-
br Use of recombinant collagen to study DDR collagen interac
2019-11-01

Use of recombinant collagen to study DDR–collagen interactions Synthetic peptides have proven highly valuable in replicating the characteristics of collagen and in defining the sites on collagen essential for binding and studying protein–collagen interactions. There are, however, disadvantages to
-
Introduction Eicosanoid lipid prostaglandin D PGD is the
2019-11-01

Introduction Eicosanoid lipid prostaglandin D2 (PGD2) is the major prostaglandin produced by activated mast potassium hydrochloride (Lewis and Austen, 1981). The physiological function of PGD2 is mainly mediated by two G protein-coupled receptors (GPCRs), PGD2 receptor 1 and 2 (DP1 and DP2), which
-
The availabilities of serotonin and dopamine
2019-11-01

The availabilities of serotonin and dopamine are modulated by the serotonin transporter and catechol-O-methyltransferase enzyme. The serotonin transporter (5-HTT) is a key protein that reuptakes serotonin from the synaptic cleft back into synaptic boutons (Coleman et al., 2016; Talvenheimo et al., 1
-
To respond to the need for QNAT commercial assays have
2019-11-01

To respond to the need for QNAT, commercial assays have been developed on automated systems. The first reagents for CMV and EBV VLs in whole blood were Abbott RealTime kits on the m2000 SP/RT system (Abbott Molecular Inc, Des plaines, USA) (M2000) [4,5] and Artus QS-RGQ kits on the QIAsymphony RGQ s
-
Significantly elevated levels of DNA damage observed in
2019-11-01

Significantly elevated levels of DNA damage observed in peripheral blood of tea garden women workers indicate the occupational exposure. The same was observed in cholinesterase activities, which detected lower activity in the exposed group compared to non-exposed. Large volumes of pesticides are use
-
Resistance to avermectins has been associated with point mut
2019-11-01

Resistance to avermectins has been associated with point mutations of GluCls in C. elegans, D. melanogaster, T. urticae and P. xylostella (Dent et al., 2000; Dermauw et al., 2012; Kane et al., 2000; Kwon et al., 2010; Wang et al., 2016a, 2017). Our electrophysiological study found a 8.2-fold reducti
-
The UPR is composed of three different
2019-11-01

The UPR is composed of three different pathways that fall under the control of three respective ER transmembrane proteins: PERK, IRE1α (inositol-requiring enzyme 1α) and ATF6 (activating transcription factor 6). As a starting signal for the UPR, misfolded proteins induce the release of GRP78 from th
-
br STAR Methods br Acknowledgments We are grateful to Amaia
2019-10-31

STAR★Methods Acknowledgments We are grateful to Amaia Lujambio, James Fagin, and Ramon Parsons for providing cell lines and Evripidis Gavathiotis for critical reading of the manuscript. We would like to thank Saboor Hekmaty for providing expertise with RNA-seq analysis. P.I.P. would like to ac
-
TraM is one of two transfer proteins from pIP T
2019-10-31

TraM is one of two transfer proteins from pIP501 T4SS that have structural similarity to the A. tumefaciens VirB8 protein (Fercher et al., 2016, Goessweiner-Mohr et al., 2013), a central member of the inner membrane complex (Bailey et al., 2006, Guglielmini et al., 2014, Trokter et al., 2014). VirB8
16149 records 946/1077 page Previous Next First page 上5页 946947948949950 下5页 Last page